PI3Kα-IN-19 (Compound 1) is a PI3Kα inhibitor with a targeted binding site at the p110α catalytic subunit. PI3Kα is one of the most common dysregulated kinases used in cancer research[1].
IC 50
p110α
References
[1] Shafiq, Muhammad et al. “A deep learning-based theoretical protocol to identify potentially isoform-selective PI3Kα inhibitors.” Molecular diversity, 10.1007/s11030-023-10799-0. 2 Feb. 2024. DOI:10.1007/s11030-023-10799-0
